# A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Study · id `cardio:ct-nct04992065` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04992065](<https://clinicaltrials.gov/study/NCT04992065>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04992065

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

## Technical summary

Registry record NCT04992065. Randomized; double masking; primary purpose treatment. Start 2021-08-03 (actual); primary completion 2022-04-26 (actual). Results posted on 2025-06-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 267 participants (enrolled count; ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Started: 2021-08-03 (actual) (ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Primary completion: 2022-04-26 (actual) (ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Completion: 2022-06-20 (actual) (ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Results first posted: 2025-06-08 (ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Countries: United States; Belgium; Germany; Greece; Japan; Netherlands; Poland (ClinicalTrials.gov record NCT04992065, source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04992065-2025-06-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): NNC0385-0434 A 15 mg
- Intervention (Drug): NNC0385-0434 A 40 mg
- Intervention (Other): Placebo I A (for NNC0385-0434 A 15 mg)
- Intervention (Drug): NNC0385-0434 A 100 mg
- Intervention (Other): Placebo I A (for NNC0385-0434 A 40 mg)
- Intervention (Other): Placebo II A (for NNC0385-0434 A 100 mg)
- Intervention (Drug): Evolocumab 140 mg/mL, Repatha®
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial (`cardio:pubmed-38310920`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 360a8072195007b79604717e6f877d841dd8a88b952a22ae568865f727e36185
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
